On a Thursday in early November, a diabetes-focused chronic care company that had long kept its hands off weight-loss prescriptions announced it would start writing them itself, a turn that arrived within hours of a federal deal promising to bring the cost of these drugs down for ordinary patients. The shift reflects a familiar pattern in modern medicine, where a field that once relied on a single family doctor now sprawls across pharmacies, apps, employers, and government programs, each trying to keep pace with a fast-changing market. Whether the new prescribing arm proves wise will depend on
Omada Health Will Prescribe GLP-1 Weight-Loss Drugs as TrumpRx Deal Slashes Costs
"The year of the Gs" begins with a price cut
Mark
Why does this reversal matter? Omada said in June it wasn't going to prescribe these drugs.
Mimi
Because the reason it gave then was member demand, and Duffy now says demand wasn't what changed. Primary care providers and employers told the company the landscape had become too complex for providers to handle alone.
Mark
So what changed in practice?
Mimi
Prices, mainly. The TrumpRx deals put Wegovy and Zepbound around $350 a month without insurance, down from over $1,000, and Medicare will cover the drugs for weight loss for the first time.
Luke
Worth separating the pieces there. The price figures are what officials said the deals will deliver. The article reports the announcement, not how it plays out for patients or when.
Mark
And the employer angle?
Mimi
Duffy says employers expect costs to rise if oral versions are approved, because cheaper pills would draw many more patients. Omada pitches itself as helping keep those costs in check.
Luke
That's Duffy's account of what employers expect. We don't have employer figures, and the oral drugs aren't FDA-approved yet, so that's a projection.
Mark
What about the coaching and tapering?
Mimi
Omada will pair prescribing with human and AI coaching, including help coming off the drugs, aimed at the rebound weight gain common after stopping.
Luke
Aimed at is the key phrase. Nothing here shows it works yet. Also, the prescribers will come from an unnamed telehealth partner, and the stock fell over 7% anyway. Plenty is still unknown.
El Pulso
- Omada Health abruptly reverses its earlier refusal to prescribe GLP-1 weight-loss drugs, announcing the change just hours after a White House drug-pricing deal.
- Employers fear total spending could balloon if cheaper oral GLP-1 pills win approval and draw far more patients into treatment.
- Omada is racing to build prescribing and coaching, leaning on a third-party telehealth partner and blending human and AI support to curb rebound weight gain.
- Investors shrugged off a revenue beat and narrowed losses, sending shares down more than 7% as doubts about profitability and a crowded market linger.
- The outcome hinges on how many employers opt in during 2026 and whether oral pills, priced at up to $149 a month, reshape both costs and demand.
On a Thursday in early November, a diabetes-focused chronic care company that had long kept its hands off weight-loss prescriptions announced it would start writing them itself, a turn that arrived within hours of a federal deal promising to bring the cost of these drugs down for ordinary patients. The shift reflects a familiar pattern in modern medicine, where a field that once relied on a single family doctor now sprawls across pharmacies, apps, employers, and government programs, each trying to keep pace with a fast-changing market. Whether the new prescribing arm proves wise will depend on what employers choose to fund and what patients, once cheaper pills arrive, actually want.
On Thursday, Omada Health, a chronic care company that went public in June and built its name on diabetes, announced it would begin prescribing GLP-1 weight-loss drugs. For months it had left those decisions to patients' primary care doctors. The reversal came only hours after President Trump unveiled a deal to lower what patients pay for the medications.
CEO Sean Duffy had told reporters at the IPO that Omada saw no steady member demand for these prescriptions and would change course only if members pushed hard for it. On Friday he explained that demand had not changed his mind. Primary care providers and employer customers had told the company that the GLP-1 market, with its shifting drug types and price points, had grown too complicated for doctors to manage alone. Employers also worried that if oral versions of the drugs win approval, far more people would want them, pushing total spending up even as each pill costs less.
The federal deal with Eli Lilly and Novo Nordisk, run through the TrumpRx discount program, aims to bring monthly out-of-pocket costs from more than $1,000 down to a range of $50 to $350. Wegovy and Zepbound would start near $350 for uninsured patients, with a goal of $250 within two years. Oral pills, not yet approved, could cost no more than $149 a month once available.
Omada says it has supported members on these drugs for years. Its new program pairs prescribing with human and AI coaching before, during, and after treatment, including help tapering off safely to avoid the weight regain that often follows stopping. Employers may opt out, and a third-party telehealth service will supply the clinicians.
Investors were unimpressed at first. Earnings and revenue beat expectations and the loss narrowed to about $3.2 million, yet the stock fell more than 7% by midday Friday, weighed by concerns about profitability and a crowded field of online GLP-1 prescribers. Duffy said he no longer tries to predict those swings. The year ahead will show how many employers sign on, and what happens to prices and demand if the pills arrive.
On Thursday, Omada Health announced that it will begin prescribing GLP-1 drugs for weight loss. The chronic care company, which went public in June and has long focused on diabetes, had until now stayed out of prescribing and left those decisions to patients' primary care providers. The reversal came only hours after President Donald Trump announced a deal to cut what patients pay for the drugs.
CEO Sean Duffy told investors on the company's third-quarter earnings call that prescribing will start in the first half of 2026. The announcement stands in contrast to what he said around the June IPO. He told Business Insider then that he wasn't seeing consistent demand from members to get GLP-1 prescriptions through Omada, and that the company would reconsider only if members pushed for it. If ten out of ten members asked for help next year, he said, the company might, but it was not the strategy.
On Friday, Duffy told Business Insider that member demand was not what changed the calculation. Primary care providers and Omada's employer customers had told the company that the fast-moving GLP-1 landscape was becoming too complicated for providers to manage alone. In his words, different types of medications at different price points were the key reason for deciding it was time to prescribe. He also said many employers expect their overall costs to rise if the FDA approves oral versions of the drugs. The pills are expected to be much cheaper, but employers assume far more patients will want them, which would increase total spending.
The administration's announcement, Duffy said, underscores exactly why Omada is offering prescribing. The deals with Eli Lilly and Novo Nordisk run through TrumpRx, the federal discount program unveiled in late September. Out-of-pocket costs are expected to fall to a range of $50 to $350 a month, compared with more than $1,000 a month for a dose now. Wegovy and Zepbound will start at around $350 a month for patients without insurance, and officials aim to bring that to $250 within two years. For the first time, Medicare will cover GLP-1 drugs for weight loss, with some qualifying patients paying a $50 monthly co-pay. Oral versions, still in development and not yet FDA-approved, would be available through TrumpRx at no more than $149 a month once they reach the market.
Omada, founded in 2011, says it has supported members on GLP-1s for years. The new prescribing program will be paired with human and AI coaching before, during, and after treatment, including help tapering off the drugs safely. The company says the aim is to keep employers' drug costs in check and to help patients avoid the rebound weight gain that is common after stopping. Employers can opt out of offering GLP-1 prescriptions. Omada will rely on a third-party telehealth service to supply the prescribing clinicians; Duffy declined to name the partner.
The move fits a broader shift at a company that had also been cautious about AI, holding off on consumer-facing tools until a few months ago. Duffy said Omada plans to double down on GLP-1s and generative AI next year, which he called "the year of the Gs."
Investors were not won over right away. Omada's third-quarter earnings and revenue beat expectations, yet the stock had fallen more than 7% by midday Friday. Analysts have raised concerns that the company is not yet profitable, though it narrowed its third-quarter loss to about $3.2 million, and that it faces a crowded digital health market with dozens of online GLP-1 prescribers. Duffy said he has stopped trying to guess at the stock's swings, calling them part of what the company signed up for.
What to watch in 2026 is how many employers opt in, and how oral GLP-1s, if approved, change both the price and the demand.
Citas Notables
Different types of meds at different price points were the key reason in deciding it's time to prescribe.— Sean Duffy, Omada Health CEO
The administration's announcement underscores exactly why Omada is offering prescribing.— Sean Duffy, Omada Health CEO (paraphrased)
Quieres la nota completa?
Lee el original en Business Insider ↗
Business